# A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

> **NCT07710157** · PHASE2 · RECRUITING · sponsor: **Medical University Innsbruck** · enrollment: 48 (estimated)

## Conditions studied

- Minimal Change Disease (MCD)

## Interventions

- **DRUG:** Obinutuzumab Injection
- **DRUG:** Predniso(lo)ne

## Key facts

- **NCT ID:** NCT07710157
- **Lead sponsor:** Medical University Innsbruck
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-13
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07710157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07710157, "A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07710157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*